Contributions
Abstract: 245
Type: Oral
Abstract Category: Pathology and pathogenesis of MS - 21 Imaging
Objective: To study the progression of neurodegeneration after two years follow-up in Relapsing-Remitting patients (RRMS) using whole brain 3D echo planar spectroscopic imaging (EPSI).
Methods: One group of 15 RRMS patients (10 women, mean age = 37 years old ± 9.7, range [23-53], median disease duration = 6.9 years ± 7.9, median EDSS = 1) was scanned at baseline (M0) and after two years (M24). A group of 21 matched healthy controls (12 women, mean age = 31 years old ± 10.9, range [21-60]) was scanned at a single time point. Weighted mean combination of the two 3D echo planar spectroscopic imaging (EPSI) acquired in the AC-PC and the AC-PC+15° axial planes was performed at M0 and M24 to obtain high quality metabolite maps covering the whole brain for two metabolites strongly linked to neurodegeneration: N-acetyl aspartate (NAA) and glutamate+glutamine (Glx). Voxel-based metabolic statistical mapping was performed between the two time points to determine progression of neurodegeneration in metabolically abnormal regions compared to controls (M0-M24 comparison in patients with paired t-test, p< 0.005, FDR corrected, masked by abnormal metabolic maps compared to controls using a two samples t-test, p< 0.005, FDR corrected).
Results: At M24, significant decreases in NAA (1 cluster, k=9622 voxels) and Glx (3 clusters, K = 2772; 1214 and 978 voxels), reflecting neuronal dysfunction and degeneration, were observed in left Thalamus, superior, median and inferior left temporal gyri, left angular gyrus, left cuneus and precuneus, splenium, brainstem, left cerebellum, right precentral cortex, right insula and median and inferior right frontal cortex compared to baseline. No significant increase in NAA and Glx was observed at M24 compared to M0.
Conclusion: We first demonstrate the ability to map non-invasively over two years the progression of neurodegeneration in functionally important regions in RRMS patients using voxel-based metabolic statistical mapping derived from whole brain 3D spectroscopic imaging.
Disclosure:
MD is the recipient of a PhD Grant (CIFRE) supported by Siemens France and the French 'Association Nationale Recherche et Technologie' (ANRT).
BA and JP received travel grants from commercial pharmaceutical companies: Biogen Idec, Novartis, Merck Serono, Bayer Schering, MedDay and Teva santé.
YLF, AAM, LP, SCG, MG and JPR have no relevant financial interest or relationship to disclose.
Abstract: 245
Type: Oral
Abstract Category: Pathology and pathogenesis of MS - 21 Imaging
Objective: To study the progression of neurodegeneration after two years follow-up in Relapsing-Remitting patients (RRMS) using whole brain 3D echo planar spectroscopic imaging (EPSI).
Methods: One group of 15 RRMS patients (10 women, mean age = 37 years old ± 9.7, range [23-53], median disease duration = 6.9 years ± 7.9, median EDSS = 1) was scanned at baseline (M0) and after two years (M24). A group of 21 matched healthy controls (12 women, mean age = 31 years old ± 10.9, range [21-60]) was scanned at a single time point. Weighted mean combination of the two 3D echo planar spectroscopic imaging (EPSI) acquired in the AC-PC and the AC-PC+15° axial planes was performed at M0 and M24 to obtain high quality metabolite maps covering the whole brain for two metabolites strongly linked to neurodegeneration: N-acetyl aspartate (NAA) and glutamate+glutamine (Glx). Voxel-based metabolic statistical mapping was performed between the two time points to determine progression of neurodegeneration in metabolically abnormal regions compared to controls (M0-M24 comparison in patients with paired t-test, p< 0.005, FDR corrected, masked by abnormal metabolic maps compared to controls using a two samples t-test, p< 0.005, FDR corrected).
Results: At M24, significant decreases in NAA (1 cluster, k=9622 voxels) and Glx (3 clusters, K = 2772; 1214 and 978 voxels), reflecting neuronal dysfunction and degeneration, were observed in left Thalamus, superior, median and inferior left temporal gyri, left angular gyrus, left cuneus and precuneus, splenium, brainstem, left cerebellum, right precentral cortex, right insula and median and inferior right frontal cortex compared to baseline. No significant increase in NAA and Glx was observed at M24 compared to M0.
Conclusion: We first demonstrate the ability to map non-invasively over two years the progression of neurodegeneration in functionally important regions in RRMS patients using voxel-based metabolic statistical mapping derived from whole brain 3D spectroscopic imaging.
Disclosure:
MD is the recipient of a PhD Grant (CIFRE) supported by Siemens France and the French 'Association Nationale Recherche et Technologie' (ANRT).
BA and JP received travel grants from commercial pharmaceutical companies: Biogen Idec, Novartis, Merck Serono, Bayer Schering, MedDay and Teva santé.
YLF, AAM, LP, SCG, MG and JPR have no relevant financial interest or relationship to disclose.